Noon Update: Moderna Add to CV19 Vaccine Good News: T&L Rallies, CV19 Stocks and Gold Sell

Another announcement of a 94% plus vaccine efficacy announced by Moderna caused almost instant market reaction with all of the indices advancing sharply  in minutes with Travel and Leisure getting the biggest boosts as IAG, CCl jumped double digits on the news, : the flip side was a sell-off in the Covid  trade as NCYT, GDR, SNG.L, ORPH, TILS and BRH all dropped double digits in the same period.

The path of least resistance now seems to the upside "reopening trade" favouring the out of home, travel and leisure sectors with oilers, transport and retail looking likely to continue to make gains

 

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2020-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).

A secondary endpoint analyzed severe cases of COVID-19 and included 11 severe cases (as defined in the study protocol) in this first interim analysis. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.

The 95 COVID-19 cases included 15 older adults (ages 65+) and 20 participants identifying as being from diverse communities (including 12 Hispanic or LatinX, 4 Black or African Americans, 3 Asian Americans and 1 multiracial).

[stock_market_widget type="inline" template="generic" assets="CCL.L" markup="{name} ({symbol}) {price} ({change_pct}){last_update}" style="font-size: small" api="yf"]

 

[stock_market_widget type="inline" template="generic" assets="NCYT.L" markup="{name} ({symbol}) {price} ({change_pct}){last_update}" style="font-size: small" api="yf"]

 

[stock_market_widget type="inline" template="generic" assets="SNG.L" markup="{name} ({symbol}) {price} ({change_pct}){last_update}" style="font-size: small" api="yf"]